Ostatní
Návod 
Supernus Pharmaceuticals, Inc.
SUPN
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
2.5B
Obrat
1B
Zisk
0B
Aktiva
1B
Dluh
0B
ROE
-2%
ROA
-1%
PE
-71
PS
4
Cena 1R
29-58
⌀ Cena
41.00
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
24-02-2026
Poslední dividenda
Profil
Supernus Pharmaceuticals, Inc., biofarmaceutická společnost, se zaměřuje na vývoj a komercializaci přípravků pro léčbu onemocnění centrálního nervového systému (CNS) ve Spojených státech. Jeho komerčními produkty jsou Trokendi XR, topiramátový přípravek s prodlouženým uvolňováním určený k léčbě epilepsie, stejně jako k profylaxi migrény a migrény bolesti hlavy; a Oxtellar XR, oxtellar XR, oxkarbazepin s prodlouženým uvolňováním k monoterapii parciálních záchvatů epilepsie u dospělých a dětí ve věku od 6 do 17 let. Komerční produkty společnosti zahrnují také Qelbree, selektivní inhibitor zpětného vychytávání norepinefrinu indikovaný k léčbě poruchy pozornosti a deficitu hyperaktivity (ATTENTION-deficit hyperactivity disorder, ADHD) u pediatrických pacientů ve věku 6 až 17 let; A N pro akutní přerušovanou léčbu hypomobility nebo off epizod u pacientů s pokročilou Parkinsonovou chorobou (PD); XADAGO pro léčbu levodopy/karbidopy u pacientů s PD, kteří mají mimo epizody; MYOBLOC, toxin typu B indikovaný k léčbě cervikální dystonie a sialdonie Dospělí; GOCOVRI pro léčbu dyskineze u pacientů s PD; a Osmolex ER pro léčbu Parkinsonovy nemoci a lékem indukované extrapyramidové reakce u dospělých pacientů. K jeho výrobkovým kandidátům dále patří Qelbree (SPN-812), který dokončil klinické zkoušky fáze III používané k léčbě ADHD; SPN-830, kombinovaný přípravek v pozdním stadiu pro prevenci epizod mimo epizodu u pacientů s PD; SPN-817, nový výrobek kandidující v klinických studiích fáze I pro léčbu těžké epilepsie; SPN-820, výrobek kandidující v klinických studiích fáze II pro léčbu rezistentní deprese; a SPN-443 a SPN-446, které jsou v předklinickém stádiu pro léčbu CNS. Společnost prodává své výrobky prostřednictvím velkoobchodníků s farmaceutickými výrobky, specializovaných lékáren a distributorů. Společnost byla založena v roce 2005 a sídlí v Rockville v Marylandu.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
674
Založení
2012-05-01
Podobné společnosti
$ 15.08
+ $ 0.13
$ 14.39
- $ 0.06
$ 38.12
- $ 0.13
$ 6.60
- $ 0.05
$ 11.51
+ $ 0.14
$ 50.59
- $ 0.48
$ 21.93
- $ 0.19
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 719.0 | 719.0 | 661.8 | 607.5 | 667.2 | 579.8 | 520.4 | 392.8 | 408.9 | 302.2 | 215.0 | 144.4 | 122.0 | 12.0 | 1.5 | 0.8 | 0.1 | |
| Cost of Revenues | 103.9 | 74.6 | 77.9 | 83.8 | 87.2 | 75.1 | 52.5 | 16.7 | 15.4 | 15.2 | 12.0 | 8.4 | 5.8 | 1.1 | 0.0 | 0.0 | -13.4 | |
| Gross Profit | 615.0 | 644.4 | 583.9 | 523.7 | 580.0 | 504.7 | 467.9 | 376.1 | 393.5 | 287.0 | 203.0 | 136.0 | 116.3 | 10.9 | 1.5 | 0.8 | 13.5 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 211.6 | 192.1 | 165.5 | 149.8 | 174.2 | 175.7 | 168.3 | 143.6 | 164.3 | 153.9 | |
| Cost of Revenues | 23.0 | 48.3 | 16.8 | 15.8 | 26.1 | 17.6 | 17.9 | 16.3 | 41.3 | 19.6 | |
| Gross Profit | 188.6 | 143.8 | 148.6 | 134.1 | 148.1 | 158.1 | 150.4 | 127.3 | 123.0 | 134.3 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 91.6 | 74.6 | 90.5 | 76.0 | 69.1 | 89.2 | 49.6 | 42.8 | 29.1 | 19.6 | 17.2 | 23.5 | 30.6 | 35.1 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 336.4 | 377.2 | 304.8 | 200.7 | 158.4 | 159.9 | 137.9 | 106.0 | 89.2 | 72.5 | 55.6 | 20.1 | 7.9 | 5.1 | |
| Depreciation & Amortization | 155.3 | 90.0 | 80.4 | 84.9 | 82.6 | 34.0 | 36.3 | 21.6 | 7.1 | 8.1 | 2.4 | 0.9 | 0.9 | 0.7 | 0.9 | 0.9 | 1.2 | |
| Total Operating Expenses | 659.5 | 681.3 | 502.2 | 529.0 | 534.4 | 425.2 | 292.3 | 227.5 | 249.1 | 187.5 | 148.8 | 118.3 | 92.1 | 72.8 | 43.6 | 38.6 | 40.2 | |
| Operating Income | -44.5 | -36.9 | 81.7 | -5.3 | 67.3 | 86.0 | 173.7 | 148.6 | 144.4 | 99.5 | 54.2 | 17.7 | 24.2 | -61.9 | -42.2 | -37.8 | -40.1 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 22.7 | 22.7 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 81.3 | 82.7 | ||
| Depreciation & Amortization | 92.2 | 21.4 | 21.4 | 20.4 | 18.8 | 20.1 | 20.7 | 20.7 | 21.7 | 21.9 | ||
| Total Operating Expenses | 174.7 | 204.0 | 136.5 | 144.3 | 126.7 | 117.3 | 127.8 | 130.5 | 104.0 | 126.6 | ||
| Operating Income | 13.8 | -60.2 | 12.1 | -10.3 | 21.4 | 40.8 | 22.6 | -3.2 | 19.0 | 8.1 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 13.3 | 13.3 | 16.2 | 10.5 | 21.7 | 10.6 | 18.7 | 21.6 | 13.8 | 2.9 | 1.5 | 0.6 | 0.4 | 0.4 | 0.1 | 0.0 | 0.1 | |
| Interest Expense | 0.0 | 0.0 | 0.0 | 2.4 | 7.1 | 23.4 | 23.8 | 22.7 | 18.1 | 1.6 | 5.1 | 1.2 | 5.0 | 7.8 | 3.6 | 1.9 | 0.1 | |
| Other Expense | -4.5 | -12.2 | 16.2 | 8.0 | -6.6 | -12.9 | -5.1 | -1.1 | -4.3 | -0.2 | -0.2 | -2.1 | 0.2 | -22.9 | -0.7 | 0.1 | 0.5 | |
| IBT | -49.0 | -49.0 | 97.9 | 2.8 | 60.7 | 73.2 | 168.6 | 147.5 | 140.2 | 100.6 | 50.4 | 15.0 | 19.9 | -92.3 | -46.3 | -39.5 | -39.5 | |
| Income Tax Expense | -10.5 | -10.5 | 24.0 | 1.5 | 0.0 | 19.8 | 41.7 | 34.4 | 29.2 | 43.3 | -40.9 | 1.0 | 4.0 | 7.1 | 1.1 | -16.2 | -0.4 | |
| Net Income | -38.6 | -38.6 | 73.9 | 1.3 | 60.7 | 53.4 | 127.0 | 113.1 | 111.0 | 57.3 | 91.2 | 14.0 | 19.9 | -92.3 | -46.3 | 56.0 | -38.5 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 2.0 | 2.3 | 4.5 | 4.4 | 5.0 | 4.1 | 3.7 | 3.4 | 2.0 | 1.8 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Other Expense | -15.7 | 2.3 | 4.5 | 4.4 | 5.0 | 4.1 | 3.7 | 3.4 | 5.7 | 1.8 | ||
| IBT | -1.9 | -58.0 | 16.7 | -5.8 | 26.4 | 44.9 | 26.3 | 0.2 | 1.0 | 9.9 | ||
| Income Tax Expense | 2.2 | -12.8 | -5.8 | 6.0 | 11.1 | 6.4 | 6.4 | 0.1 | -0.2 | 25.9 | ||
| Net Income | -4.1 | -45.1 | 22.5 | -11.8 | 15.3 | 38.5 | 19.9 | 0.1 | 1.2 | -16.0 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.02 | $1.13 | $1.01 | $2.41 | $2.16 | $2.13 | $1.13 | $1.84 | $0.29 | $0.47 | $-2.90 | $-2.65 | $3.64 | $-2.78 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 | $0.28 | $0.32 | $-2.90 | $-2.65 | $3.64 | $-2.78 | |
| Shares Outstanding | 57.3 | 56.5 | 55.1 | 54.5 | 53.7 | 53.1 | 52.6 | 52.4 | 52.0 | 50.8 | 49.5 | 47.5 | 42.3 | 31.8 | 17.4 | 13.9 | 13.9 | |
| Diluted Shares Outstanding | 57.3 | 56.5 | 56.0 | 55.5 | 61.7 | 54.4 | 53.7 | 53.8 | 54.1 | 53.3 | 51.7 | 51.2 | 50.6 | 31.8 | 17.4 | 13.9 | 13.9 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $-0.29 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $-0.29 | ||
| Shares Outstanding | 57.3 | 56.4 | 56.0 | 55.9 | 55.5 | 55.1 | 55.0 | 54.8 | 54.6 | 54.6 | ||
| Diluted Shares Outstanding | 57.3 | 56.6 | 56.6 | 55.9 | 56.5 | 56.0 | 55.7 | 55.6 | 55.3 | 54.6 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 52.1 | 69.3 | 75.1 | 93.1 | 203.4 | 288.6 | 181.4 | 192.2 | 100.3 | 90.1 | 62.2 | 74.3 | 82.2 | 88.5 | 48.5 | 23.7 | |
| Short Term Investments | 295.1 | 384.3 | 179.8 | 368.2 | 136.2 | 133.9 | 165.7 | 163.8 | 39.7 | 23.7 | 28.0 | 37.9 | 49.2 | 48.2 | 0.0 | 9.0 | |
| Total Cash & ST Investments | 347.2 | 453.6 | 254.9 | 461.3 | 339.7 | 422.5 | 347.1 | 356.0 | 140.0 | 90.1 | 62.2 | 74.3 | 82.2 | 88.5 | 48.5 | 32.7 | |
| Accounts Receivable | 152.5 | 142.1 | 144.2 | 165.5 | 148.9 | 140.9 | 87.3 | 102.9 | 65.6 | 41.5 | 25.9 | 17.3 | 5.1 | 0.7 | 0.1 | 0.2 | |
| Inventory | 68.2 | 54.3 | 77.4 | 91.5 | 86.0 | 48.3 | 26.6 | 25.7 | 16.3 | 16.8 | 12.6 | 13.4 | 7.2 | 1.2 | 0.4 | 6.8 | |
| Other Current Assets | 23.2 | 36.1 | 16.7 | 15.8 | 27.0 | 18.7 | 11.6 | 8.9 | 6.5 | 3.0 | 5.3 | 3.8 | 2.8 | 3.2 | 0.3 | 0.2 | |
| Total Current Assets | 591.0 | 686.1 | 493.1 | 734.2 | 601.6 | 630.4 | 472.6 | 493.5 | 228.5 | 151.4 | 106.0 | 108.9 | 97.2 | 91.7 | 49.4 | 39.8 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 151.4 | 144.7 | 115.8 | 69.3 | 31.7 | 52.1 | 63.4 | 75.1 | 95.0 | 24.7 | |
| Short Term Investments | 129.8 | 377.9 | 347.7 | 384.3 | 371.5 | 295.1 | 234.3 | 179.8 | 105.2 | 127.0 | |
| Total Cash & ST Investments | 281.2 | 522.6 | 463.6 | 453.6 | 403.2 | 347.2 | 297.7 | 254.9 | 200.2 | 151.7 | |
| Accounts Receivable | 171.3 | 140.8 | 145.6 | 142.1 | 145.4 | 152.5 | 147.7 | 144.2 | 141.8 | 136.6 | |
| Inventory | 79.4 | 44.0 | 49.4 | 54.3 | 64.0 | 68.2 | 75.1 | 77.4 | 83.5 | 90.6 | |
| Other Current Assets | 62.1 | 31.4 | 28.9 | 36.1 | 27.4 | 23.2 | 23.8 | 16.7 | 23.9 | 44.8 | |
| Total Current Assets | 593.9 | 738.9 | 687.6 | 686.1 | 640.0 | 591.0 | 544.3 | 493.1 | 449.4 | 423.5 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 40.0 | 11.5 | 42.5 | 15.2 | 17.0 | 37.8 | 38.3 | 4.1 | 5.1 | 4.3 | 3.9 | 2.4 | 2.6 | 1.4 | 1.3 | 1.2 | |
| Goodwill | 117.0 | 117.0 | 117.0 | 117.0 | 117.5 | 77.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 559.6 | 521.9 | 599.9 | 702.5 | 784.7 | 442.3 | 24.8 | 31.4 | 36.0 | 16.5 | 1.0 | 5.4 | 1.2 | 0.7 | 0.9 | 1.1 | |
| Long-Term Investments | -11.4 | 0.0 | 16.6 | 93.9 | 119.2 | 350.4 | 591.8 | 418.8 | 133.6 | 75.4 | 55.0 | 19.8 | 8.8 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 8.1 | 31.5 | 8.5 | -10.0 | -36.1 | 8.0 | 0.6 | 0.4 | 0.4 | 20.2 | 0.4 | 6.4 | 1.5 | 0.1 | 2.1 | 4.8 | |
| Total Long-Term Assets | 724.8 | 682.0 | 784.6 | 968.4 | 1,087.6 | 873.7 | 687.6 | 484.3 | 196.0 | 158.2 | 82.8 | 28.6 | 13.8 | 2.2 | 4.3 | 7.2 | |
| Total Assets | 1,315.8 | 1,368.1 | 1,277.7 | 1,702.5 | 1,689.2 | 1,504.1 | 1,160.3 | 977.8 | 424.5 | 309.6 | 188.7 | 137.5 | 111.0 | 94.0 | 53.7 | 47.0 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 10.6 | 11.1 | 11.3 | 11.5 | 11.9 | 12.3 | 13.0 | 42.5 | 13.7 | 14.2 | |
| Goodwill | 119.1 | 117.0 | 117.0 | 117.0 | 117.0 | 117.0 | 117.0 | 117.0 | 117.0 | 117.0 | |
| Intangible Assets | 623.5 | 481.3 | 502.1 | 521.9 | 540.2 | 559.6 | 579.8 | 599.9 | 641.1 | 662.4 | |
| Long-Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.7 | 16.6 | 25.1 | 37.5 | |
| Other Long-Term Assets | 72.7 | 28.0 | 29.2 | 31.5 | 33.6 | 35.9 | 38.4 | 8.5 | 3.6 | -5.8 | |
| Total Long-Term Assets | 825.9 | 643.5 | 659.7 | 682.0 | 702.7 | 724.8 | 759.8 | 915.9 | 835.8 | 869.6 | |
| Total Assets | 1,419.8 | 1,382.4 | 1,347.3 | 1,368.1 | 1,342.7 | 1,315.8 | 1,304.1 | 1,409.0 | 1,285.2 | 1,293.1 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.6 | 4.6 | 2.0 | 96.3 | 117.7 | 78.9 | 10.1 | 3.2 | 6.8 | 8.1 | 4.3 | 1.9 | 18.3 | 10.7 | 10.1 | 11.3 | |
| Short-Term Debt | 9.7 | 6.9 | 8.3 | 402.0 | 6.5 | 3.8 | 2.8 | 0.0 | 111.6 | 69.4 | 0.0 | 0.0 | -18.5 | 11.8 | 6.8 | 0.0 | |
| Other Current Liabilities | 294.3 | 280.9 | 279.9 | 139.8 | 65.0 | 40.0 | 3.2 | 158.2 | 4.3 | 3.1 | 51.6 | 25.5 | 18.5 | 0.0 | 1.7 | 3.9 | |
| Current Liabilities | 308.7 | 292.4 | 290.2 | 688.0 | 315.4 | 245.1 | 160.6 | 161.4 | 123.0 | 80.7 | 56.1 | 27.5 | 26.4 | 23.0 | 18.8 | 15.2 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 108.6 | 8.2 | 7.1 | 4.6 | 6.4 | 4.6 | 14.4 | 2.0 | 3.4 | 4.4 | |
| Short-Term Debt | 0.0 | 7.4 | 5.9 | 6.9 | 9.2 | 9.7 | 9.1 | 8.3 | 8.5 | 8.0 | |
| Other Current Liabilities | 222.0 | 270.8 | 268.8 | 280.9 | 275.9 | 294.3 | 291.0 | 279.9 | 275.7 | 240.2 | |
| Current Liabilities | 330.6 | 286.4 | 281.8 | 292.4 | 291.5 | 308.7 | 314.6 | 290.2 | 287.5 | 252.6 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 30.3 | 27.4 | 33.2 | 36.0 | 420.6 | 390.3 | 375.6 | 329.5 | 0.0 | 4.2 | 7.2 | 26.9 | 34.4 | 11.1 | 22.7 | 75.0 | |
| Capital Leases | 30.3 | 34.3 | 41.5 | 36.0 | 41.3 | 28.6 | 30.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 11.4 | 5.0 | 25.0 | 49.8 | 85.4 | 35.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 6.6 | 12.6 | -0.3 | 0.9 | 0.0 | |
| Total Liabilities | 358.4 | 332.3 | 356.2 | 816.3 | 873.3 | 759.2 | 564.9 | 524.8 | 157.0 | 117.8 | 69.9 | 66.2 | 77.5 | 36.4 | 44.3 | 91.3 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 31.4 | 24.4 | 26.4 | 27.4 | 28.9 | 30.3 | 33.0 | 33.2 | 33.8 | 34.2 | |
| Capital Leases | 31.4 | 31.8 | 32.3 | 34.3 | 38.2 | 40.0 | 42.1 | 33.2 | 42.3 | 42.2 | |
| Def. Tax Liability | 0.0 | 0.0 | 1.0 | 5.0 | 7.4 | 11.4 | 19.5 | 156.3 | 35.2 | 44.3 | |
| Total Liabilities | 370.1 | 318.5 | 316.6 | 332.3 | 335.6 | 358.4 | 374.9 | 487.5 | 373.0 | 373.2 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | 502.6 | 556.4 | 482.6 | 481.2 | 379.9 | 326.5 | 199.5 | 86.5 | -26.8 | -84.3 | -144.6 | -158.7 | -178.5 | -86.3 | -40.0 | -93.8 | |
| Comprehensive Income | -0.4 | -0.2 | -0.6 | -3.2 | 1.5 | 9.0 | 7.4 | -3.2 | -0.7 | -0.1 | -0.5 | -0.2 | 0.0 | -0.1 | 0.0 | 0.0 | |
| Total Common Equity | 957.5 | 1,035.7 | 921.5 | 886.2 | 815.9 | 744.9 | 595.4 | 453.0 | 267.5 | 191.8 | 118.9 | 71.4 | 33.5 | 57.6 | 9.4 | -44.3 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | 522.0 | 567.1 | 544.6 | 556.4 | 541.1 | 502.6 | 482.7 | 482.6 | 481.4 | 497.4 | |
| Comprehensive Income | -0.1 | -0.2 | -0.2 | -0.2 | 0.1 | -0.4 | -0.5 | -0.6 | -1.2 | -1.8 | |
| Total Common Equity | 1,049.7 | 1,063.9 | 1,030.7 | 1,035.7 | 1,007.2 | 957.5 | 929.2 | 921.5 | 912.2 | 919.9 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 40.0 | 34.3 | 41.5 | 438.0 | 420.6 | 390.3 | 375.6 | 329.5 | 0.0 | 4.2 | 7.2 | 26.9 | 34.4 | 22.9 | 29.5 | 75.0 | |
| Book Value | 957.5 | 1,035.7 | 921.5 | 886.2 | 815.9 | 744.9 | 595.4 | 453.0 | 267.5 | 191.8 | 118.9 | 71.4 | 33.5 | 57.6 | 9.4 | -44.3 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 1,049.7 | 1,063.9 | 1,030.7 | 1,035.7 | 1,007.2 | 957.5 | 929.2 | 921.5 | 912.2 | 919.9 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 5.2 | -38.6 | 73.9 | 1.3 | 60.7 | 53.4 | 127.0 | 113.1 | 111.0 | 57.3 | 91.2 | 14.0 | 19.9 | -92.3 | -46.3 | -23.2 | -39.1 | |
| Depreciation & Amortization | 85.0 | 90.0 | 80.4 | 84.9 | 85.5 | 32.6 | 18.1 | 6.7 | 7.1 | 8.1 | 2.4 | 0.9 | 0.9 | 0.7 | 0.9 | 0.9 | 1.2 | |
| Stock-Based Compensation | 26.8 | 33.1 | 27.8 | 26.8 | 17.6 | 17.9 | 16.6 | 14.8 | 11.3 | 8.4 | 5.9 | 4.2 | 2.7 | 1.9 | 0.4 | -0.1 | 0.3 | |
| Change Working Capital | 42.6 | -75.2 | -2.1 | -9.1 | -24.2 | 3.6 | -36.5 | 0.6 | -4.7 | 23.7 | 8.4 | 10.1 | -17.5 | 5.7 | -3.2 | 0.2 | 5.9 | |
| Change In Accounts Receivable | -15.9 | -22.3 | 2.1 | 18.8 | -16.4 | 3.9 | -34.6 | 15.8 | -35.9 | -24.1 | -15.6 | -8.6 | -12.2 | -5.0 | 0.0 | -0.1 | 0.3 | |
| Change In Accounts Payable | -9.1 | -24.6 | -15.0 | -36.3 | -19.2 | 18.2 | 8.3 | 7.0 | -3.6 | -0.6 | 3.5 | 2.1 | -1.3 | 8.5 | -1.1 | -1.1 | 5.2 | |
| Change In Inventories | 20.0 | -7.5 | 15.8 | 6.1 | -17.9 | -14.6 | -10.1 | -1.0 | -9.4 | 0.5 | -4.2 | 0.9 | -6.3 | -6.0 | -1.2 | 0.1 | 0.3 | |
| Other Non-cash Items | 127.0 | 32.7 | 12.1 | 33.0 | 3.6 | 24.6 | 12.7 | 13.8 | 8.5 | -4.1 | 0.6 | 0.7 | 2.1 | 3.0 | 0.3 | 2.3 | -0.4 | |
| Cash from Operations | 154.9 | 0.0 | 0.0 | 111.1 | 116.8 | 127.1 | 138.4 | 143.1 | 129.0 | 114.6 | 66.8 | 32.1 | 7.7 | -57.9 | -47.2 | -36.2 | -32.5 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -38.6 | -45.1 | 22.5 | -11.8 | 15.3 | 38.5 | 19.9 | 0.1 | 1.2 | -16.0 | |
| Depreciation & Amortization | 92.2 | 24.8 | 21.4 | 20.4 | 18.8 | 20.1 | 20.7 | 20.7 | 21.7 | 21.9 | |
| Stock-Based Compensation | 33.1 | 7.8 | 7.5 | 8.1 | 7.6 | 7.7 | 6.6 | 5.9 | 6.4 | 7.9 | |
| Change Working Capital | -51.4 | -49.2 | 11.5 | 13.9 | -5.1 | -7.9 | -2.9 | 13.9 | 2.0 | 29.7 | |
| Change In Accounts Receivable | -16.4 | -7.1 | 4.8 | -3.6 | 3.3 | 7.1 | -4.8 | -3.6 | -2.4 | -5.2 | |
| Change In Accounts Payable | -0.5 | -21.5 | -6.5 | 3.9 | -0.4 | -11.8 | -12.8 | 10.0 | -0.3 | -6.1 | |
| Change In Inventories | -4.2 | -12.9 | 4.9 | 4.7 | 3.2 | 4.6 | 6.0 | 2.0 | 5.0 | 6.9 | |
| Other Non-cash Items | -20.7 | 2.7 | 2.8 | 4.1 | 7.8 | 1.6 | -0.5 | 3.2 | 24.1 | 1.7 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 45.0 | 35.9 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.4 | -1.3 | -0.7 | -0.6 | -0.4 | -2.0 | -3.4 | -2.7 | -0.8 | -2.0 | -1.6 | -2.1 | -0.6 | -2.4 | -0.8 | -0.7 | -0.3 | |
| Acquisitions | 0.0 | -293.1 | 0.0 | 0.0 | 0.0 | -311.7 | -313.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | |
| Investments | -419.3 | -475.9 | -688.0 | -101.6 | -407.0 | -311.6 | -95.9 | -409.7 | -491.7 | -101.9 | -47.4 | -63.2 | -53.3 | -85.6 | -97.7 | -17.9 | -32.8 | |
| Sales of Investment | 288.2 | 774.9 | 498.9 | 370.9 | 190.7 | 530.5 | 378.4 | 253.2 | 79.8 | 28.7 | 31.8 | 37.6 | 53.5 | 75.8 | 49.5 | 26.9 | 58.9 | |
| Other Investing Activities | -16.6 | 0.0 | 0.0 | 0.0 | 0.0 | 12.9 | -0.2 | 1.3 | -0.8 | -11.2 | -18.8 | -8.5 | -4.5 | -0.7 | 0.0 | 25.6 | 0.0 | |
| Cash from Investing | -131.6 | 0.0 | 0.0 | 268.7 | -216.7 | -81.9 | -34.7 | -157.9 | -413.5 | -86.4 | -36.0 | -36.2 | -4.9 | -12.1 | -49.0 | 33.9 | 25.8 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -1.3 | -0.1 | -0.5 | -0.3 | -0.2 | -0.2 | -0.1 | -0.2 | 0.0 | -0.2 | |
| Acquisitions | -293.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -475.9 | -126.6 | -140.6 | -118.6 | -145.4 | -224.9 | -124.0 | -193.7 | -101.6 | 0.0 | |
| Sales of Investment | 774.9 | 468.6 | 110.4 | 156.2 | 133.0 | 148.1 | 75.5 | 142.3 | 35.6 | 34.8 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 34.8 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -66.0 | 34.6 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -495.5 | 0.0 | 0.0 | -402.5 | 0.0 | -138.3 | -0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -24.3 | -6.8 | 0.0 | 0.0 | |
| Debt Issued | 493.3 | 34.3 | -7.3 | 6.1 | 17.4 | 168.5 | 15.5 | 46.1 | 329.5 | -4.2 | -3.0 | -19.8 | -7.4 | 35.8 | 0.2 | -45.5 | 75.0 | |
| Issuance of Common Stock | 7.4 | 0.0 | 0.0 | 6.6 | 12.4 | 7.1 | 4.4 | 3.9 | 11.6 | 5.7 | 2.1 | 1.9 | 0.6 | 2.4 | 100.7 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -3.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -3.1 | 0.0 | 0.0 | -2.0 | -22.9 | 0.8 | 0.0 | 0.0 | 364.9 | 0.0 | 0.0 | 0.0 | 0.0 | 84.6 | -6.0 | 27.1 | -0.9 | |
| Cash from Financing | 4.1 | 0.0 | 0.0 | -397.9 | -10.5 | -130.4 | 3.6 | 3.9 | 376.4 | 5.7 | 2.1 | 1.9 | 0.6 | 62.7 | 87.9 | 27.1 | -0.9 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 31.4 | -0.4 | -0.5 | -2.0 | -3.9 | -1.8 | -2.2 | 0.6 | -0.8 | 0.1 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1 | 0.7 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.0 | 0.0 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | -0.2 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 27.4 | 60.6 | -5.7 | -18.1 | -110.3 | -85.2 | 107.3 | -10.9 | 91.9 | 33.9 | 32.9 | -2.2 | 3.4 | -7.3 | -8.2 | 24.8 | -7.7 | |
| Closing Cash Balance | 52.1 | 129.9 | 69.3 | 75.1 | 93.1 | 203.4 | 288.6 | 181.4 | 192.2 | 100.3 | 66.4 | 34.2 | 36.4 | 33.0 | 40.3 | 48.5 | 23.7 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -22.9 | 8.1 | 28.9 | 46.5 | 37.7 | -20.4 | -11.3 | -11.7 | -19.9 | 70.3 | |
| Closing Cash Balance | 129.9 | 152.8 | 144.7 | 115.8 | 69.3 | 31.7 | 52.1 | 63.4 | 75.1 | 95.0 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 154.4 | 46.0 | 171.2 | 110.5 | 116.4 | 125.1 | 135.0 | 140.4 | 128.1 | 112.6 | 65.2 | 30.0 | 7.1 | -60.3 | -48.0 | -36.9 | -32.8 | |
| Real Free Cash Flow | 127.6 | 12.9 | 143.5 | 83.8 | 98.8 | 107.2 | 118.4 | 125.5 | 116.9 | 104.2 | 59.3 | 25.8 | 4.4 | -62.2 | -48.4 | -36.8 | -33.1 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 19.4 | -61.8 | 58.1 | 30.3 | 44.2 | 53.3 | 35.6 | 38.2 | 45.0 | 35.7 | |
| Real Free Cash Flow | -13.6 | -69.6 | 50.6 | 22.2 | 36.6 | 45.6 | 29.0 | 32.3 | 38.5 | 27.8 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -71 | 21.8 | 2356.8 |
| P/S | 3.8 | 12 | 70.5 |
| P/B | 2.6 | 13 | 2015.4 |
| P/FCF | -261.9 | 15 | 7573.5 |
| Market cap | $2.5 | $10.3 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 2.2 % | 26.6 % | 0 % |
| Debt to Income | -81.5 % | 218.2 % | 0 % |
| Debt to Free cash flow | -300.5 % | 235.5 % | 0 % |
| Interest expense percentage | 0 % | 8.7 % | 26.2 % |
| Current ratio | 1.8 | 2.5 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -3.7 % | 349.7 % | 0 % |
| ROA | -2.7 % | 3.2 % | 0 % |
| CapEx to Revenue | 0.1 % | 5.4 % | 6 % |
| RaD to Revenue | 0 % | 65.4 % | 0 % |
| ROEM | 1,066,694.4 | 500699.6 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 84.3 % | 81.4 % | 74.8 % |
| Operating margin | -5.4 % | -144.8 % | 35 % |
| Net margin | -2.8 % | -272.4 % | 34.1 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 56.6 mil | 45.1 mil |
| Employee count | 0.7 tis | 0.5 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
